Oral Carnitine Supplementation Reduces Body Weight And Insulin Resistance In Women With Polycystic Ovary Syndrome: A Randomized, Double-blind, Placebo-controlled Trial
Notes for this study:
||Change from baseline as mean ± SD (μmol/l): Placebo (−0·59 ± 3·20) vs L-Carnitine (−3·64 ± 7·00); p = 0·03
|Number of Subjects
This randomized, double-blind, placebo-controlled trial investigated the effectiveness of L-carnitine on weight loss, and glycaemic and lipid profiles in females with polycystic ovary syndrome (PCOS).
For 12 weeks, the intervention group (n = 30) took 250 mg/day L-carnitine while the control group (n = 30) took a placebo. At the studies end, the L-carnitine saw small to moderate improvements in weight, BMI, WC, HC, and glycaemic control. It did not affect lipid profiles or free testosterone.